Choi YH, et al. – In this modelling study, researchers assessed the potential impact of a 1+1 (3, 12 month) schedule on invasive pneumococcal disease (IPD) and pneumococcal community-acquired pneumonia (CAP). The investigators’ results and those from a 1+1 immunogenicity study comprised the key evidence reviewed by the United Kingdom Joint Committee on Vaccination and Immunisation. According to findings, with the current mature status of the PCV program in England and Wales, eliminating one chief dose in the first year of life would likely have little impact on IPD or pneumococcal CAP cases or associated deaths at any age. However, a decrease in the number of priming doses might improve programmatic efficiency and facilitate the introduction of new vaccines by decreasing the number of co-administered vaccines given at 2 and 4 months of age in the current UK schedule. Overall, the investigators noted that their findings should not be applied to other settings with different pneumococcal epidemiology or with immature programs and poor herd immunity.